维普期刊资源整合服务平台（V6.5）

26篇 您的检索式：作者名="Kahn JB"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Latest industry information on the safety profile of levofloxacin in the US显示文摘	Kahn JB	2001	Chemotherapy2001，47，3：	1
2	Latest industry information on the safety profile of levofloxacin in the US 显示文摘	Kahn JB	2001	Chemotherapy2001，47，3：	1
3	Efficacy of 750 mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens 显示文摘	Dunbar LM Khashab MM Kahn JB	2004	Curr Med Res Opin2004，20，4：	1
4	Latest industry information on the safety profile of levofloxacin in the US 显示文摘	Kahn JB	2001	Chemotherapy2001，47，3：	1
5	Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens显示文摘	Dunbar LM Khashab MM Kahn JB	2004	Curr Med Res Opin2004，20，4：	1
6	When children with ka wasaki disease grow up myocardial and vascular complica tions in adulthood显示文摘	Gordon JB Kahn AM Burns JC	2009	J Am Coil Cardiol2009，54，21：	1
7	Comparison of the adverse event profiles of levofloxacin 500 mg and 750mg in clinical trials for the treatment of respiratory infections显示文摘	Khashab MM Xiang J Kahn JB	2006	Curt MedRes Opin2006，22，10：	1
8	Latest industry information on the safety profile of levofloxacin in the US显示文摘		2001	Chemotherapy2001，47，3：	1
9	Calcium scoring in patients with a history of kawasaki disease 显示文摘	Kahn AM Matthew JB Daniels LB	2012	JACC : Cardiovasc Imaging2012，3，：	1
10	When children with Kawasaki disease grow up:myocardial and vascular complications in adulthood显示文摘	Gordon JB Kahn AM Burns JC	2009	J Am Coll Cardiol2009，54，21：	1
11	Efficacy of 750 mg, 5 day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens显示文摘	Dunbar LM Khashab MM Kahn JB	2004	Curr Med Res Opin2004，20，4：	1
12	When children with Kawasakidisease grow up:Myocardial and vascular complications in adult-hood显示文摘	Gordon JB Kahn AM Burns JC	2009	Am Coll Cardiol2009，54，21：	1
13	Efficacy of 750 mg,5 day levo-floxacin in the treatment of community-acquired pneumonia caused by a-typical pathogens显示文摘	Dunbar LM Khashab MM Kahn JB e( al	2004	Curr Med Res Opin2004，20，4：	1
14	Latest industry information on the safety profile of levofloxacin in the US显示文摘	Kahn JB	2001	Chemotherapy2001，47，3：	1
15	Effect of drug type on the degradation rate of PLGA matrices 显示文摘	Siegel SJ Kahn JB Metzger K	2006	Eur J Pharm Biopharm2006，64，3：	1
16	Efficacy of 750- mg, 5-day levofloxaein in the treatment of communityacquired pneumonia caused by atypical pathogens 显示文摘	Dunbar LM Khashab MM Kahn JB	2004	Curt Med Res Opin2004，20，4：	1
17	Latest industry information on the safety profile of levofloxacin in the US显示文摘		2001	Chemotherapy2001，47，3：	1
18	When children with Ka- wasaki disease grow up: myocardial and vascular complica- tions in adulthood显示文摘	C-ordon JB Kahn AM Burns JC	2009	J Am Coil Cardiol2009，54，21：	1
19	Latest industry information on the safety profile oflevofloxacinintheUS显示文摘	Kahn JB	2001	Chemotherapy2001，47，3：	1
20	Comparison of the adverse of levofloxacin 500 mg and 750 mg in clinical trials for the treatment of respiratory infections显示文摘	Khashab MM Xiang J Kahn JB	2006	Curt Med Res Option2006，22，10：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示